# Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

> **NCT07497399** · PHASE2 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 120 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** NLY01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07497399
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2030-01
- **Final completion:** 2030-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07497399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07497399, "Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07497399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*